Effectiveness of MD on MetS Patients

Assiut University

Status: Not yet enrolling

Conditions: Obesity

Treatments: Dietary Supplement: MD

Study type: Interventional

Funder types: Other

Identifiers

NCT06961682

Fam Med Dep AssiutU

Details and patient eligibility

About

The metabolic syndrome (MetS), is a complicated condition linked to coronary artery disease.This group includes visceral obesity (abdominal or android type obesity), insulin resistance (IR), hypertension, and dyslipidaemia.The global prevalence of MetS is estimated to be about one-quarter of the world population or over a billion global citizens .A high MetS prevalence of 55% was found in Egyptians, 85.6% among diabetics, and 76.6% among hypertensive patients .People can modify their diet, physical activity, decrease smoking habits to lower their chance of developing MetS. Frequent exercise can lower blood pressure while increasing insulin sensitivity, lipolysis, and energy expenditure. It has the ability to improve blood lipid parameters .Diet is one of the most important tools available to improve MetS. However, the diet for the prevention and treatment of MetS remains unspecified beyond weight control and reduction in total calories. Several evidences show that it should generally be low in saturated fats, trans fats, cholesterol, sodium and simple sugars .The adherence to the Mediterranean Diet(MD) brings up two positive features, firstly the activity levels are increased and secondly the environmental impact becomes self-rewarding. The more the MD is favoured, the more the self-productivity is achieved resulting in a stronger life style adaptation .MD causes reduction of CVD incidence and outcomes decreases BP (systolic and diastolic) , inverses association with mortality,improvements in dyslexia, decreases incidence of T2DM.

Enrollment: 170 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

1. Inclusion criteria:

   All people diagnosed as metabolic syndrome

   • (Hypertension(systolic BP≥130 or Diastolic BP ≥85)
   • prediabetes fasting plasma glucose(100-125),oral glucose tolerance test(140-199)Hba1c(5.7-6.4)ADA
   • Diabetes, fasting>125, oral glucose tolerance test>200, Hba1c≥6.5 ADA .
   • Hyperlipidaemia(TG≥150 mg\dl-HDL<40 in male and <50 in female) [12]
   • Obesity(waist circumference ≥102cm in male and ≥88cm in female) [12]

2. Exclusion criteria:

   • Type 1 diabetes
   • Patients with renal or advanced liver disease(Failure)
   • Oral contraceptives, psychiatric, neurologic medications and steroid therapy
   • Patients with heart failure and presence of stent
   • Endocrine disease (Thyroid disease especially hypothyroidism-Cushing disease)

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

170 participants in 1 patient group

Metabolic syndrome patients attending Assiut university hospital

Experimental group

Description:

MetS patients with diabetes, hypertension, dyslipidemia and obesity at least three criteria to diagnose the metabolic syndrome

Treatment:

Dietary Supplement: MD